Skip to main content
Premium Trial:

Request an Annual Quote

Nova Satra Nabs $2M Investment

NEW YORK (GenomeWeb) – Singapore-based molecular diagnostics firm Nova Satra today announced a US$2 million investment from Genting Bio Cellular, a wholly owned subsidiary of investment and management firm Genting Berhad.

The funds will be used for regulatory approvals and commercialization of Nova Satra's lead test, a noninvasive blood-based test for breast cancer, which leverages an epigenetic platform technology developed at the University of Oxford. The test relies on highly stable DNA-based targets as part of chromosomal signatures instead of unstable protein/RNA molecules that other molecular diagnostics rely on, the company said.

In conjunction with the financing, Genting Bio Cellular acquired the exclusive rights to distribute the test in Malaysia. Two directors nominated by Genting also joined Nova Satra's board.

The company said that it also intends to make available a pipeline of molecular diagnostic tests across multiple cancers.

Nova Satra CoFounder and CEO Kane Black said that the investment provides the firm with capital resources and "substantial operation support to our research, development, and commercialization program." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.